Table of contents
- Original news
- What does this mean for the industry?
- What will happen next?
- Are pharmaceutical companies likely to make changes to their processes and procedures?
- How will the Statement of Objection impact the pharmaceutical industry?
- How should practitioners advise clients in this sector in light of this development?
Article summary
Competition analysis: The European Commission has issued a Statement of Objections to pharmaceutical company Lundbeck and other drugs companies in relation to ‘pay-for-delay’ deals concluded with four generic competitors. The formal objections against the companies have been served in an attempt to ease market entry for cheaper generic medicines and it is understood to be the EU’s first case investigating pay-for-delay agreements. Bernardine Adkins, partner and head of the antitrust team at Wragge, says it is not a black and white issue and doubts the development will have an immediate effect.
To continue reading this news article, as well as thousands of others like it, sign in with LexisNexis or register for a free trial